ASX RELEASE

Paradigm Successfully Doses First Participant In Phase 2 Ross River Virus Clinical Trial

Key Highlights:

- Successful dosing of first participant in Phase 2 Alphavirus clinical trial of Pentosan Polysulfate Sodium (PPS) for the treatment of Ross River virus
- First participant was treated at the Barwon Health site in Geelong and is the first participant to be enrolled in the trial
- Trial commencement signifies strong momentum and depth in Paradigm's clinical trial pipeline, making it the Company's fourth active clinical trial since listing on the ASX
- Trial will recruit 24 participants with Ross River virus in Victoria and Queensland
- Trial subjects will be evaluated for safety, tolerability and effects on disease symptoms, with results anticipated in Q2 CY2018

Melbourne, 9 August 2017, Paradigm Biopharmaceuticals Ltd (ASX:PAR) announces that it has successfully dosed its first participant in its Phase 2 Alphavirus clinical trial of the drug Pentosan Polysulfate Sodium (PPS) for the treatment of Ross River virus.

The first participant was treated at the Barwon Health site in Geelong and is the first participant to be enrolled in the trial which is being conducted across two sites in Victoria and Queensland.

The commencement of the trial signifies strong momentum and depth in Paradigm's clinical trial pipeline, making it the Company's fourth active clinical trial since listing on the ASX.

The randomised, double-blinded placebo-controlled clinical trial will treat a total of 24 subjects across both the Victorian and Queensland sites. Patients with RRV induced arthralgia (painful joints) will be evaluated for safety, tolerability and effects on disease symptoms of PPS subcutaneous injections, with results anticipated in mid 2018.

The incidence of Ross River virus in Victoria has spiked so far this year, with high amounts of rainfall and warm weather resulting in an unusually high number of infections. A total of 1,911 cases have been identified in the year to date to 30 July 2017 – an 86.2% increase on 2016's total of 263 cases[1].

Mr Paul Rennie, Paradigm's CEO said, "We hope that PPS can prove to be an effective treatment for Ross River virus. New treatments for the condition are desperately needed, especially in Victoria, where the rates of the disease have increased significantly, representing a large unmet medical need."

[1] Source: Health Vic, Surveillance of notifiable conditions in Victoria, 15 June 2017: http://www.health.vic.gov.au/ideas/downloads/daily_reports/rptVS_SNIDSVictorianSummary_GR.pdf

“Whilst current therapeutics can help to manage the joint pain associated with the virus, they have not been shown to treat the detrimental effects on joint cartilage that are associated with the disease.”

The commencement of participant dosing follows ethics approval being received for both the Victorian and Queensland trial sites. This confirms that the trial is ethically acceptable and in accordance with relevant standards and guidelines for research involving humans as set out by the Australian National Health and Medical Research Council.

The dosing of the first participant also follows research conducted by Griffith University in RRV disease models, and subsequent phase 2 trial design work completed by Paradigm in consultation with experts in alphaviral disease. It also follows Paradigm and Griffith University receiving a non-dilutive grant of AU$300,000 from the Queensland Government during the quarter to accelerate the development of PPS to treat Ross River virus.

Paradigm continues its discussions with the US Department of Defense re the development of PPS for a treatment for Chikungunya virus infections.

FOR FURTHER INFORMATION PLEASE CONTACT:

Paul Rennie
Director & CEO
Paradigm BioPharmaceuticals Ltd
Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA
ABN: 94 169 346 963
Web: http://paradigmbiopharma.com/
Email: prennie@paradigmbiopharma.com
Mobile International: +61 437 778 300
Mobile (Australia): 0437 778 300